Data Shows Positive Signs for Legal Cannabis Industry

Tuesday, February 6, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

FinancialBuzz.com News Commentary

NEW YORK, February 6, 2018 /PRNewswire/ --

According to a report

by Grand View Research, the global medical cannabis market is projected to reach a value of USD 55.8 billion by 2025. After the elections of 2016, Washington D.C. along with 28 states has
legalized cannabis for medical uses. The growing number of states and countries getting approval for using it in therapeutic applications is one of the crucial factors driving the demand over the coming few years. Grand View indicates that several regulatory frameworks such as the Medical Marijuana Regulation and Safety Act will require individuals or companies associated, such as growers, retail operators, and makers of processed pot products to obtain permission and an annual state license from 2018. Helix TCS Inc. (OTC: HLIX), United Cannabis Corporation (OTC: CNAB), Innovative Industrial Properties, Inc. (NYSE: IIPR), Innovative Industrial Properties, Inc. (NYSE: IIPR), Cannabis Sativa, Inc. (OTC: CBDS), Vitality Biopharma, Inc. (OTC: VBIO)

Starting January 1st 2018, the state of California has started legal sales of cannabis products for recreational use. Tom Adams, Editor-in-Chief at Arcview Market Research and Principal Analyst at BDS Analytics explained: "Our data shows positive indicators across the board for the legal cannabis industry, in North America and around the globe… The passage of the 2016 ballot initiatives and continued maturation of the existing Adult-Use markets are the primary drivers of the growth this year. That's nothing compared to what we can expect in 2018 and beyond from Nevada's tourism, and California and Canada planning to launch Adult-Use sales in 2018."

Helix TCS Inc. (OTCQB: HLIX) just earlier today the company announced breaking news that, "along with its investment partner Rose Capital, acquired all of the outstanding preferred stock of Bio-Tech Medical Software, Inc. (or BioTrackTHC). This investment represents approximately 18.5% of BioTrackTHC's outstanding capital stock, on an as-converted to common basis. In addition, Helix CEO Zac Venegas will join BioTrackTHC's board.

"As we continue to execute our strategy of offering integrated operating services to the legal cannabis industry, we are excited to forge a stronger relationship with BioTrackTHC and work towards providing our clients with ways to operate with greater efficiency, security, compliance, and profitability," stated Mr. Venegas.

Since its founding in 2015, Helix continues to grow in scale and scope in the legal cannabis industry, operating in the security, transportation and compliance sectors. In 2016, it acquired Cannabase, the industry's oldest electronic wholesale marketplace.  

"We are impressed with BioTrackTHC's growth and geographic footprint for seed-to-sale systems. Furthering our relationship with BioTrackTHC is an important step in our finding ways to support the technology and data capabilities of all of our business lines, including Cannabase," stated Venegas.

Helix TCS, Inc. is a premier provider of integrated operating environment solutions for the legal cannabis industry.  Helix provides a proprietary software suite and partnership platform to the legal cannabis industry, helping clients manage inventory and supply costs and bespoke monitoring and transport solutions.  Helix provides clients in the legal cannabis industry high standard security operations, including transportation, armed and unarmed guarding, training, investigation, and special services.

United Cannabis Corporation (OTCQB: CNAB) is a biotechnology company dedicated to the development of phyto-therapeutic based products supported by patented technologies for the pharmaceutical, medical, and industrial markets. Recently, the company announced that it has established a Limited Partnership between the Company, LASCO Manufacturing Limited (LASCO) and United Cannabis' Jamaican Partner, Cannabinoid Research & Development Co. Ltd. LASCO, one of the leading dry blend beverage companies in Jamaica, reported revenue of $56.2 million in 2017, with products exported to 22 countries throughout the Caribbean, Central and South America, Canada, United Kingdom, and the United States.The Company also announced that it has signed an exclusive License Agreement (the "Agreement") with LASCO to produce the Company's CBD water and other Bio Nutrient Medicinals in the form of Capsules, Sublinguals, Roll-ons, and Balms for the English-speaking Caribbean and Central America, excluding Mexico.

Innovative Industrial Properties, Inc. (NYSE: IIPR) is a self-advised Maryland corporation focused on the acquisition, ownership and management of specialized industrial properties leased to experienced, state-licensed operators for their regulated medical-use cannabis facilities. On December 18, 2017, the company announced that it closed on the previously announced acquisition of the property located at 5900 West Greenhouse Drive in Willcox, Arizona, which comprises approximately 358,000 square feet of greenhouse and industrial space. The Pharm is one of the largest wholesalers of medical-use cannabis in the state of Arizona. Concurrent with the closing of the purchase, the Company entered into a long-term, triple-net lease agreement with a subsidiary of The Pharm, which intends to continue to operate the property as a medical-use cannabis cultivation and processing facility in accordance with Arizona medical-use cannabis regulations.

Cannabis Sativa, Inc. (OTCQB: CBDS) is engaged in the licensing of cannabis related intellectual property, marketing and branding for cannabis based products and services, operation of cannabis related technology services, and ancillary business activities. CBDS licenses the "hi" and "White Rabbit" brands, holds a U.S. patent on the Ecuadorian Sativa strain of Cannabis, owns patent pending and trade secret formulas and processes, offers the hi benefits discount pharmacy card, and operates subsidiaries including: PrestoDoctor, Wild Earth Naturals, and iBudtender. On December 4, 2017, the company announced that its subsidiary, PrestoDoctor, is expanding its online medical marijuana recommendation services into New York. PrestoDoctor currently serves patients via both their online platform and with dispensary kiosks operating in California and Nevada and will now extend their online services to patients located in the State of New York.

Vitality Biopharma, Inc. (OTCQB: VBIO) is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. On January 17, 2018, the company announced it has submitted an orphan drug designation request for VITA-100 to the U.S. Food & Drug Administration. Upon approval, VITA-100 would be designated as an orphan drug for the treatment of pediatric ulcerative colitis (UC), a form of pediatric inflammatory bowel disease.  The U.S. Orphan Drug Act (ODA) of January 1983 is meant to encourage development of drugs for rare diseases, and review by the FDA's Office of Orphan Products Development can expedite the evaluation and eventual market approval of products that demonstrate significant promise for the treatment of these conditions. Vitality Biopharma's gut-targeted cannabosides enable delivery of THC without psychoactivity or intoxication, which may enable more widespread use of cannabinoids for treatment of pediatric digestive disorders.  The Company has already completed studies that demonstrate the efficacy of cannabosides for treatment of preclinical models of colitis.  Cannabosides were able to reduce weight loss, decrease damage to the colon, and markedly improve gastrointestinal health compared to the placebo controls.

Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com  

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For financial news dissemination and PR services, FinancialBuzz.com has not been compensated by any company mentioned. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com .

For further information: Media Contact: info@financialbuzz.com , +1-877-601-1879 Url: http://www.FinancialBuzz.com

SOURCE FinancialBuzz.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store